** Shares of Abbott Laboratories ABT.N fall 2.85% to $126.19
** A judge in the Whitfield infant formula case granted a retrial to the plaintiffs following the October 31, 2024 verdict that handed a unanimous win in favor of Abbott and Reckitt's RKT.L unit Mead Johnson
** The ruling found the companies were not liable for failing to warn of the risks around necrotizing enterocolitis $(NEC.AU)$ in their infant formula products
** Today's ruling marks a setback following what seemed like a step in the right direction - J.P.Morgan
** ABT shares up ~8% in the last 12 months
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。